BRIEF published on 11/04/2024 at 11:51, 1 year 3 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 3 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 3 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 3 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 6 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 1 year 6 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 1 year 8 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 1 year 8 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 02/07/2026 at 01:00, 1 day 2 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 4 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 5 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 11 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 13 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 6 hours 20 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 10 hours 45 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 11 hours ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 7 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 9 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 8 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 11 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 9 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
